MPT0G211 mesylate is a potent, orally active, and selective HDAC6 inhibitor (IC50 = 0.291 nM) with >1000-fold selectivity over other HDAC isoforms; it crosses the blood-brain barrier and ameliorates tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease models; exhibits anti-metastatic and neuroprotective effects; demonstrates anticancer activity.